A

xovant Sciences (AXON), 2017’s most talked-about biotech company, is abandoning the drug that made it famous after yet another clinical trial failure.

The company, valued at more than $2.8 billion in September, will no longer study intepirdine after finding the drug to be useless against dementia with Lewy bodies, a memory-destroying disease that can affect mood and balance. Last year, intepirdine failed in a 1,300-patient Alzheimer’s disease trial, sending Axovant’s share price down more than 75 percent.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • I think this is true of all psychiatric drugs – the drugs work only due to their “placebo effect” and also have terrible side effects as well as long-term adverse effects.

    For Alzheimer’s – future research should focus on psychological causes. Numerous studies have consistently shown that it is ‘human experiences,’ (especially psychological stresses) that gradually bring about changes in the brain (this is called ‘neuroplasticity’). The ‘Einstein Aging Study’ showed that psychological stress lead to cognitive impairment.
    [see: Katz, M. J., et al. (2016). Influence of Perceived Stress on Incident Amnestic Mild Cognitive Impairment: Results From the Einstein Aging Study. Alzheimer disease and associated disorders, 30(2), 93-98.].
    Research has also demonstrated that mindfulness practices reduce stress and also result in healthy structural and functional changes in the brain.

    The trouble with giving drugs (using someone’s idea of “treating” mental illnesses) is that they interfere with complex biochemical pathways of the brain with adverse effects in the long term, making matters worse.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.